Navigation Links
VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
Date:11/6/2007

SAN FRANCISCO and ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today presented data showing that VIA-2291 significantly inhibited vascular inflammation in a mouse model of atherosclerosis. VIA-2291, the company's lead drug candidate, is a potent, selective and reversible inhibitor of 5-lipoxygenase (5-LO), which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis).

The data were presented at the Inflammation and Adhesion Molecules II session at the American Heart Association Scientific Sessions 2007 in Orlando, FL (poster: B138).

"These data further validate our human clinical trial program with VIA-2291," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "By targeting this key pathway in vascular inflammation, we believe VIA-2291 may have the potential to reduce the major adverse cardiac events that occur as a result of the rupture of unstable plaque. We are encouraged that these data support VIA-2291 as a potential, powerful anti-inflammatory compound for the vascular system."

Atherosclerosis is the result of chronic inflammation and the buildup of plaque in arterial blood vessel walls. Research in both humans and mice has noted abundant expression of 5-LO co-localizing with macrophages in aortic lesions. These cells are often implicated in vascular inflammation in atherosclerosis.

The study used mice that were genetically modified to develop atherosclerosis. A team of researchers headed by Thomas Quertermous, M.D., chief of the
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... Safety Concerns Raised ... NEW YORK, Dec. 5 Keryx Biopharmaceuticals,(Nasdaq: KERX ... (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral,gelcaps), the Company,s ... nephropathy, recently met to evaluate the data from,the ongoing ...
... N.J., Dec. 5 Senesco,Technologies, Inc. ("Senesco" or ... it has initiated preclinical lab studies at Mayo ... test the ability of,Senesco,s Factor 5A gene technology ... will evaluate delivery molecules for,encapsulation of Factor 5A ...
Cached Medicine Technology:Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 2Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 3Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 4Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 5Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 6Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... wheat that boosts up the protein, zinc and iron ... that affect millions of children worldwide. Researchers at the ... the U.S. Department of Agriculture; and the University of ... the Nov. 24 issue of the journal Science. ...
... there is one more impact of a job burn out. ... also stir up a host of ailments, say Scientists. //This ... stress at work can contribute to high blood pressure, metabolic ... 677 workers in Israel revealed that risk of Type 2 ...
... School of Medicine have reported that genetics has a ... preemies//, a disease known to hamper the development of ... This report is published in the November issue of ... show that genetic factors are a significant component of ...
... Scientists at San Francisco, in the US, have announced ... positive results. // ,This treatment referred to as ... of brain cancer, termed glioma.Scientists at the University of ... mode of treatment involves isolating a protein gp96 from ...
... Vietnam, The Nha Trang Institute of Vaccines and Biological ... 5,000 doses of a H5N1 vaccine for// humans from ... on white mice, guinea-pigs and cockerels and similar reactions ... Institute of Verification of Vaccines and Biological Products. Its ...
... Michelle Hasni of Cutler Ridge, Miami, delivered a male child ... very rare congenital heart disorder called Ectopia// cordis. Seven or ... defect. ,The baby named Naseem, was born with ... and the protective cover for the heart called pericardium had ...
Cached Medicine News:Health News:Newly Cloned Wheat Gene May Boosts Foods' Nutrient Contents – Says A Researc 2Health News:Genetics Plays A Crucial Role In Preemies' Destructive Eye Disease 2Health News:Naseem’s Heart Put In Its Plac 2
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: